{
    "root": "b776ccd0-5894-416d-879e-0d7ca6f6cfd9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Valacyclovir Hydrochloride"
    },
    "value": "20250522",
    "ingredients": [
        {
            "name": "VALACYCLOVIR HYDROCHLORIDE",
            "code": "G447S0T1VC"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "PEG-20 SORBITAN OLEATE",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POVIDONE K90",
            "code": "RDH86HJV5Z"
        },
        {
            "name": "CI 77891",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "Valacyclovir hydrochloride is a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients (1.1) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-1-infected patients Reduction of transmission Herpes Zoster Pediatric Patients (1.2) Cold Sores (Herpes Labialis) Chickenpox Limitations of Use (1.3) The efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-1-infected patients.",
    "contraindications": "Valacyclovir tablets may be given without regard to meals.\n                     Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500 mg valacyclovir tablets for use in pediatric patients for whom a solid dosage form is not appropriate [see Dosage and Administration (2.3)].",
    "warningsAndPrecautions": "Product:    50090-1173\n                  NDC:    50090-1173-0   15 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-1173-1   21 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-1173-2   30 TABLET, FILM COATED in a BOTTLE\n                  NDC:    50090-1173-3   90 TABLET, FILM COATED in a BOTTLE",
    "adverseReactions": "Valacyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valacyclovir, acyclovir, or any component of the formulation [see Adverse Reactions (6.3)]."
}